Drug Trial Radar · NCT05590260
Prevention of Iron Deficiency Anemia Post-delivery
Last checked: Nov 20, 2026Latest source record: Jul 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,857
Actual
Start
May 30, 2023
Primary completion
Mar 10, 2025
Study completion Jul 28, 2025
Sponsor
- Lead sponsor
- NICHD Global Network for Women's and Children's HealthResearch network
- Sponsor type
- Research network
- Collaborators
- Thomas Jefferson University; University of North Carolina, Chapel Hill; Kinshasa School of Public Health; University of Alabama at Birmingham; University Teaching Hospital, Lusaka, Zambia; University of Colorado, Denver; Institute of Nutrition of Central America and Panama; University of Virginia; International Centre for Diarrhoeal Disease Research, Bangladesh; Columbia University; Aga Khan University; Boston University; Lata Medical Research Foundation, Nagpur; Indiana University; Moi University; RTI International; Bill and Melinda Gates Foundation; KLE University Jawaharlal Nehru Medical College
- First posted
- Oct 21, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 15 years, up to 49 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
PRIORITY is designed as a 2-arm, randomized-controlled trial focused on postpartum women. The trial will recruit women who are diagnosed with moderate anemia based on a blood sample taken 6-48 hours after childbirth. A total of 4,800 eligible women, or 600 women per research site, will be consented and enrolled in the trial. The study hypothesizes that at 6 weeks postpartum, the incidence of achieving a non-anemic state (defined as Hb ≥11 g/dL) will be greater among women receiving a single-dose infusion of IV iron than among women receiving standard care with oral iron.
Conditions
- Postpartum Anemia
Interventions
Ferric carboxymaltose (FCM) and folic acid tabletsDrug
FCM 50 mg iron/mL will be in a solution of 20 mL vials for infusion, using a dosage of 20 mg elemental iron per kg body weight, up to a maximum of 1 g, in a single IV infusion over 20-30 minutes. 400 mcg of folic acid daily to 6 months.
Oral iron tablets and folic acid tabletsDrug
60 mg elemental iron twice daily to 6-weeks with then once or twice daily (based on Hb at 6-weeks) to 6-months. 400 mcg of folic acid daily to 6 months.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maternal non-anemic state (Hb ≥11 g/dL)Time frame: 6 weeks post-delivery
Locations
8 sites in 7 countries. Site status is shown where the registry gives one.
ICDDRB
Dhaka, Bangladesh
Kinshasa School of Public Health
Kinshasa, Democratic Republic of the Congo
INCAP
Guatemala City, Guatemala
Lata Medical Research Foundation
Nagpur, India, India
KLE Society's Jawaharlal Nehru Medical College
Belagavi, Karnataka, India
Moi University School of Medicine
Eldoret, Kenya
The Aga Khan University
Karachi, Pakistan, Pakistan
University Teaching Hospital
Lusaka, Zambia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.